estrone-sulfate and Prostatic-Hyperplasia

estrone-sulfate has been researched along with Prostatic-Hyperplasia* in 1 studies

Other Studies

1 other study(ies) available for estrone-sulfate and Prostatic-Hyperplasia

Article	Year
Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). The Journal of steroid biochemistry and molecular biology, 2008, Volume: 109, Issue:1-2 Seeking insight into the possible role of estrogens in prostate cancer (PCa) evolution, we assayed serum E2, estrone (E1), and estrone sulfate (E1S) in 349 PCa and 100 benign prostatic hyperplasia (BPH) patients, and in 208 control subjects in the same age range (50-74 years). E1 (pmol/L+/-S.D.) and E1S (nmol/L+/-S.D.) in the PCa and BPH patients (respectively 126.1+/-66.1 and 2.82+/-1.78, and 127.8+/-56.4 and 2.78+/-2.12) were significantly higher than in the controls (113.8+/-47.6 and 2.11+/-0.96). E2 was not significantly different among the PCa, BPH, and control groups. These assays were also carried out in PCa patients after partition by prognosis (PSA, Gleason score (GS), histological stage, and surgical margins (SM)). Significantly higher E1S levels were found in PCa with: PSA>10 ng/L (3.05+/-1.92) versus PSAor=4+3 (109.5+/-43.8) versus GS Topics: Adult; Aged; Androgens; Biomarkers, Tumor; Blood Chemical Analysis; Case-Control Studies; Estradiol; Estrone; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values	2008

Article

Year

Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).

The Journal of steroid biochemistry and molecular biology, 2008, Volume: 109, Issue:1-2

Seeking insight into the possible role of estrogens in prostate cancer (PCa) evolution, we assayed serum E2, estrone (E1), and estrone sulfate (E1S) in 349 PCa and 100 benign prostatic hyperplasia (BPH) patients, and in 208 control subjects in the same age range (50-74 years). E1 (pmol/L+/-S.D.) and E1S (nmol/L+/-S.D.) in the PCa and BPH patients (respectively 126.1+/-66.1 and 2.82+/-1.78, and 127.8+/-56.4 and 2.78+/-2.12) were significantly higher than in the controls (113.8+/-47.6 and 2.11+/-0.96). E2 was not significantly different among the PCa, BPH, and control groups. These assays were also carried out in PCa patients after partition by prognosis (PSA, Gleason score (GS), histological stage, and surgical margins (SM)). Significantly higher E1S levels were found in PCa with: PSA>10 ng/L (3.05+/-1.92) versus PSAor=4+3 (109.5+/-43.8) versus GS

Topics: Adult; Aged; Androgens; Biomarkers, Tumor; Blood Chemical Analysis; Case-Control Studies; Estradiol; Estrone; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values

2008